Solid Biosciences (SLDB) AI Stock Analysis

• Market Cap: $440.97M
• Dividend Yield: N/A
• Average Volume (3M): 954.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: N/A
• EPS Growth: 17.88%
• Country: US
• Employees: 100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 77,910,240
• 10 Day Avg. Volume: 1,086,005
• 30 Day Avg. Volume: 954,671
• PEG Ratio: 0.04
• Price to Book (P/B): 1.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.62
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -464.51
• Enterprise Value/Ebitda: -2.23
• 1Y Price Target: $15.11
• Price Target Upside: 166.96% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -2.04
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $5.50 ▼(-2.83% Downside)

The score is held down primarily by very weak fundamentals—zero TTM revenue, widening losses, and significant ongoing cash burn—despite a relatively low-debt balance sheet. Technicals are moderately supportive with neutral-to-positive momentum, but valuation remains difficult to justify on earnings due to the negative P/E and no dividend.

Positive Factors

Strong Cash Position

A strong cash position relative to debt provides the company with a buffer to manage operations and invest in R&D, crucial for biotech firms.

Focus on Rare Diseases

Focusing on rare diseases like DMD offers potential for high-impact treatments and market exclusivity, enhancing long-term growth prospects.

Strategic Alliances

Strategic alliances can provide critical resources and expertise, enhancing development capabilities and potential market reach.

Negative Factors

Persistent Losses

Ongoing financial losses without revenue generation strain resources and may limit the company's ability to sustain operations long-term.

Negative Cash Flow

Negative cash flow highlights inefficiency in operations, increasing reliance on external funding and posing liquidity risks.

No Revenue Growth

Lack of revenue growth limits financial flexibility and raises concerns about the company's ability to achieve profitability.

Solid Biosciences Business Overview & Revenue Model

Company Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Solid Biosciences generates revenue primarily through the development and potential commercialization of its gene therapy programs targeting Duchenne muscular dystrophy. The company's revenue streams include collaborations and partnerships with other biotechnology and pharmaceutical companies, grants, and potential milestone and royalty payments from licensing agreements. Additionally, Solid Biosciences may derive future revenues from the successful approval and commercialization of its proprietary therapies, which would include sales revenue from products reaching the market. The company's focus on innovative treatments and strategic alliances are key factors contributing to its financial prospects.

Solid Biosciences Financial Statement Overview

Summary

Solid Biosciences is facing significant financial challenges, with persistent losses and an inability to generate revenue. The company's reliance on equity financing is evident, which provides some short-term stability but is unsustainable in the long run without revenue generation. The overall financial health requires strategic shifts to achieve revenue growth and operational efficiency to ensure long-term viability.

Income Statement

Solid Biosciences has shown consistent challenges in generating revenue, with no revenue reported for the last two years. The lack of revenue growth and persistent negative EBIT and net income margins highlight ongoing operational struggles. The company’s gross profit margin is non-existent due to zero revenue, and the net profit margin is significantly negative, reflecting substantial losses. Overall, the income statement presents a challenging financial position with no clear path to profitability in the near term.

Balance Sheet

The balance sheet shows a moderate level of financial stability with a strong cash position relative to debt, resulting in negative net debt, which is a positive aspect. However, the debt-to-equity ratio remains low, indicating limited leverage, which might restrict growth opportunities. The equity ratio is healthy, suggesting that the company is primarily financed through equity, reducing financial risk. However, the continuous erosion of equity due to losses is a concern for long-term sustainability.

Cash Flow

The cash flow statement indicates challenges in generating positive cash flow, with negative operating and free cash flows. Despite some cash inflows from financing activities, the company is heavily reliant on external funding to sustain operations. The free cash flow to net income ratio is unfavorable, highlighting inefficiency in converting operations into cash. There is a consistent negative trend in cash flow metrics, posing liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	8.09M	13.62M	0.00
Gross Profit	-793.00K	-2.46M	-2.58M	8.09M	13.62M	-3.92M
EBITDA	-165.28M	-121.90M	-93.43M	-96.87M	-69.29M	-84.37M
Net Income	-167.13M	-124.70M	-96.02M	-85.98M	-72.19M	-88.29M
Balance Sheet
Total Assets	273.91M	188.66M	164.94M	260.25M	232.38M	171.17M
Cash, Cash Equivalents and Short-Term Investments	236.14M	148.92M	123.64M	213.72M	207.78M	154.74M
Total Debt	21.94M	24.18M	26.27M	28.55M	2.06M	5.15M
Total Liabilities	55.97M	51.42M	38.46M	48.59M	24.17M	39.08M
Stockholders Equity	217.95M	137.25M	126.48M	211.67M	208.21M	132.09M
Cash Flow
Free Cash Flow	-133.17M	-100.67M	-95.69M	-100.99M	-79.05M	-57.50M
Operating Cash Flow	-132.38M	-100.01M	-94.18M	-97.98M	-77.76M	-56.60M
Investing Cash Flow	-66.90M	-16.09M	9.69M	59.16M	-91.09M	6.60M
Financing Cash Flow	196.24M	122.44M	3.12M	74.83M	134.99M	128.70M

Solid Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLDB, the sentiment is Positive. The current price of 5.66 is above the 20-day moving average (MA) of 5.58, above the 50-day MA of 5.23, and above the 200-day MA of 4.97, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.43 is Neutral, neither overbought nor oversold. The STOCH value of 61.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLDB.

Solid Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLUE	75 Outperform	$1.84B	77.64	9.28%	―	1112.27%	―
AUTL	56 Neutral	$383.24M	-1.63	-60.52%	―	407.86%	30.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADCT	48 Neutral	$439.76M	-2.50	―	―	6.35%	39.57%
SLDB	47 Neutral	$440.97M	-2.19	-86.83%	―	―	17.88%
KRRO	42 Neutral	$82.87M	-0.93	-63.46%	―	―	21.61%

Solid Biosciences Corporate Events

Solid Biosciences Reports Positive Interim Data on SGT-003

On November 3, 2025, Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, highlighting the safety, tolerability, and efficacy of SGT-003 in treating Duchenne muscular dystrophy. The trial, which has dosed 23 participants across multiple countries, showed strong correlations between SGT-003 microdystrophin therapy and improvements in muscle integrity biomarkers, suggesting a potential breakthrough in gene therapy for Duchenne. The company plans to discuss potential accelerated approval pathways with the FDA in 2026, while also progressing with its Phase 3 IMPACT DUCHENNE trial and other clinical programs.

The most recent analyst rating on (SLDB) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Solid Biosciences stock, see the SLDB Stock Forecast page.